

Amanda R Moore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9031340/publications.pdf>

Version: 2024-02-01

9
papers

1,201
citations

933447

10
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

2310
citing authors

#	ARTICLE	IF	CITATIONS
1	RAS-targeted therapies: is the undruggable drugged?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 533-552.	46.4	569
2	Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. <i>Nature Genetics</i> , 2016, 48, 675-680.	21.4	236
3	Spliceosomal disruption of the non-canonical BAF complex in cancer. <i>Nature</i> , 2019, 574, 432-436.	27.8	163
4	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. <i>Cell Reports</i> , 2018, 22, 2455-2468.	6.4	75
5	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	27.8	64
6	Combined Inhibition of G1±q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1476-1490.	7.0	29
7	Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. <i>Journal of Biological Chemistry</i> , 2021, 296, 100163.	3.4	22
8	A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. <i>PLoS ONE</i> , 2016, 11, e0161084.	2.5	18
9	The promise and peril of KRAS G12C inhibitors. <i>Cancer Cell</i> , 2021, 39, 1059-1061.	16.8	10